Volastra Therapeutics
PrivateLast Round
Series B
Sep 23, 2025
Total Funding Raised
$166.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Volastra Therapeutics is a biotechnology company that develops oncology therapeutics targeting chromosomal instability to treat metastatic cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Volastra Therapeutics Comparables
Compare Volastra Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Simcere Pharmaceutical Group | 76% | |
| Apeiron Therapeutics | 74% | |
| China National Machinery Industry Corporation | 74% |
Volastra Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 23, 2025 | ||||
| Series A | Mar 7, 2023 | ||||
| Seed | Apr 6, 2021 | ||||
| Seed | Feb 11, 2020 |
Key People
Founding team and executive leadership
Volastra Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| B Capital Group | Series B |
| ARCH Venture Partners | Seed, Series A |
| Vida Ventures | Seed, Series A |
| Droia Ventures | Seed, Series A |
| Catalio Capital Management | Seed, Series A |
| ARCH Venture Partners | Seed, Series A |
| Cornell University Office of University Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 78% MoM, reaching 4K.
- May 31, 2026
Two assets, VLS-1488 and Sovilnesib, granted designation by the FDA.
Volastra Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Volastra Therapeutics's valuation, stock price, and market status.
Is Volastra a public or private company?
Volastra is a private company.
What is the current stock price of Volastra?
Volastra is a private company with no public stock price. No recent secondary market data is available.
How much is Volastra worth (valuation)?
Valuation information for Volastra is not publicly available.
Can I buy Volastra stock?
Volastra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Volastra's last funding round?
Volastra's most recent funding round was Series B on September 23, 2025.
Who are the main investors in Volastra?
Key investors in Volastra include Vida Ventures, Catalio Capital Management, ARCH Venture Partners, Polaris Partners, Quark Venture.
Will Volastra IPO soon?
No public IPO plans have been announced for Volastra.
How can I track Volastra secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Volastra's secondary market activity and sign up for updates.